GEM vs GEM+TS-1 for Advanced Pancreatic Cancer
Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tokyo, Japan, 135-8550
- Cancer Institute Ariake Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically proven unresectable pancreatic carcinoma
- There must be measurable lesions with multislice CT
- ECOG Performance status 0-2
- No other active cancer
- No previous therapy such as radiotherapy, chemotherapy and immunotherapy
- Adequate organ functions are preserved as WBC more than 4000/mm3,Hb more than 8.0g/dl,neutrophil more than 2000/mm3,platlet more than 100,000/mm3, AST less than 2.5 x normal or less than 5.0 x normal if the patient had known liver metastasis, bilirubin less than 2.0mg/dl, Ccr more than 60ml/min
- No serious complications
- Be able to eat food
- Life expectancy of more than 8 weeks duration
- Informed consent is obtained-
Exclusion Criteria:
- Interstitial pneumonia
- Uncontrollable diabetes, liver dysfunction, angina pectoris,or myocardial infarction with its onset within 3 months
- Serious infection
- Pregnant or lactating females
- History of serious drug allergy
- Serious other complications
- Uncontrolled mental disorders -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
gemcitabine + S-1
|
gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
Other Names:
|
|
Active Comparator: 2
S-1
|
gemcitabine DIV on day one , 8th and 15th
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
response rate
Time Frame: during observation
|
during observation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
median survival time(MST)
Time Frame: during observation
|
during observation
|
|
time-to-progression(TTP)
Time Frame: from onset of regression to progression
|
from onset of regression to progression
|
|
toxicity
Time Frame: during observation
|
during observation
|
|
clinical benefit response
Time Frame: during observation
|
during observation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Takaaki Ikari, MD. PhD, Cancer Institute Ariake Hospital
- Principal Investigator: Masafumi Suyama, M.D. PhD, Juntenndo University Hospital
- Principal Investigator: Naoto Egawa, M.D. PhD, Komagome Hospital
- Principal Investigator: Yasuji Omuro, M.D. PhD, Komagome Hospital
- Principal Investigator: Takao Itoi, M.D. PhD, Tokyo medical college
- Principal Investigator: Atsushi Sofuni, M.D. PhD, Tokyo medical college
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
Other Study ID Numbers
- JACCRO PC-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.